Sartorius Stedim Biotech Release: New Webinar On Faster cGMP Manufacturing Scale-up Of Biotherapeutics

Featuring an Industry Case Study from FUJIFILM Diosynth Biotechnologies Showing use of the ambr® 250 for Rapid Optimisation of Processes to Manufacturing

Cambridge, UK – April 27, 2015: Sartorius Stedim Biotech (SSB) today announced that it will be presenting a new bioprocess webinar with FUJIFILM Diosynth Biotechnologies on Wednesday, May 13th at 09.00 BST/London (10.00 CEST/Berlin, 16.00 CST/Beijing, 17.00 KST/Seoul) and again at 08.00 PDT/San Francisco (11.00 EDT/Boston, 16.00 BST/London, 17.00 CEST/Berlin). The live events will detail how to use the ambr® 250 automated mini bioreactor system to make bioprocess scale-up both quicker and easier.

During the one hour webinar, Mwai Ngibuini, ambr 250 Product Manager, at SSB, will detail the functional features of the ambr 250 system with its independent, parallel control of 12 or 24 single-use bioreactors (100-250 mL working volume) controlled by an automated workstation. He will then describe the potential of the ambr 250 system to accelerate bioprocess development with industry data demonstrating the consistency and scalability to bench top bioreactors.

Dr Fern Slingsby, R&D Upstream Development Scientist at major contract development and manufacturing organisation, FUJIFILM Diosynth Biotechnologies will present how her team is using the ambr 250 to perform a Design of experiments (DoE) approach using Quality by Design (QbD) principles to produce highly soluble protein titres in E.coli. She will then detail how this fermentation process can be optimised in just four weeks demonstrating how the ambr 250 can contribute to rapid process improvement and effective scale-up to cGMP manufacturing of biotherapeutics.

To register for these live webinars, scientists can visit: http://view6.workcast.net/register?cpak=5854318252906025

Mwai Ngibuini, ambr 250 Product Manager, at SSB stated: "I am looking forward to hosting a webinar with bioprocessing expert, Dr Fern Slingsby, where she will discuss how the ambr 250 is being used to accelerate bioprocessing in a major biopharmaceutical manufacturing development facility.”

Ngibuini concluded: “Scientists that need to reduce their timelines for process scale-up should register today for this exciting webinar to learn more about how ambr 250 can contribute to faster and more cost-effective manufacturing of their biotherapeutics.”

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.

ambr® systems are designed and manufactured by TAP Biosystems (now part of the Sartorius Stedim Biotech Group) a leading global provider of automated cell culture and fermentation systems for life science research, development and production. ambr systems are widely used for cell line development and process optimisation at pharmaceutical, biotechnology and academic laboratories. They are proven to provide a reliable model and consistent scalability to a range of upstream processes.

Help employers find you! Check out all the jobs and post your resume.

Back to news